Sanofi extends deal with CytoReason

Monday 23 January 2023


Sanofi SA has expanded a collaboration with CytoReason Ltd, the Israeli technology company, to include inflammatory bowel disease (IBD) in a project that uses artificial intelligence to discover novel disease targets. The two companies have been working together since 2021, initially to identify targets for treating asthma.